Instrument Inactif

Autres langues Stellar Biotechnologies Inc Toronto S.E.

Actions

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS	24/06
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	10/05
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	12/04
Edesa Biotech to Participate in Barclays Global Healthcare Conference	08/03
Top Premarket Gainers	05/03
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	09/02
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/12
Top Premarket Decliners	13/12
Top Premarket Gainers	22/11
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	20/11
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug	26/10/23
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/10/23
Top Premarket Decliners	13/10/23
Sector Update: Health Care Stocks Decline in Late Afternoon	12/10/23
Sector Update: Health Care	12/10/23
Top Midday Gainers	12/10/23
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/10/23
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/10/23
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate	29/09/23
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	28/09/23

Aucun résultat pour cette recherche